Dexverapamil and Epirubicin in Metastatic Breast Cancer
Author Information
Author(s): M Lehnert, K Mross, J Schueller, B Thuerlimann, N Kroeger, H Kupper
Primary Institution: Kantonsspital St Gallen
Hypothesis
Can dexverapamil enhance the effectiveness of epirubicin in patients with non-responsive metastatic breast cancer?
Conclusion
The addition of dexverapamil to epirubicin resulted in partial responses in some patients without increasing toxicity.
Supporting Evidence
- Dexverapamil did not increase epirubicin toxicity.
- The area under the plasma concentration-time curve of epirubicin was significantly reduced by dexverapamil.
- Partial responses were observed in 4 out of 23 patients evaluable for tumor response.
- The mean trough plasma levels of dexverapamil and its major metabolite were 1.2 and 1.5 µM respectively.
Takeaway
Doctors tested a new drug called dexverapamil to see if it could help another drug, epirubicin, work better for women with tough breast cancer. Some women got better when they took both drugs together.
Methodology
Patients received epirubicin alone, and those with refractory disease were given dexverapamil alongside epirubicin.
Potential Biases
Potential bias due to the lack of randomization and the small number of patients evaluated for response.
Limitations
The study had a small sample size and lacked a control group.
Participant Demographics
Thirty-nine women aged 18-65 with metastatic breast cancer.
Statistical Information
P-Value
0.02
Confidence Interval
5-39%
Statistical Significance
p=0.02
Want to read the original?
Access the complete publication on the publisher's website